...
首页> 外文期刊>Journal of International Medical Research >Effects of Losartan on Fibrinolytic Parameters and von Willebrand Factor in Chinese Subjects with Hypertension: A Comparative Study versus Atenolol
【24h】

Effects of Losartan on Fibrinolytic Parameters and von Willebrand Factor in Chinese Subjects with Hypertension: A Comparative Study versus Atenolol

机译:氯沙坦对中国高血压患者纤溶参数和von Willebrand因子的影响:与阿替洛尔的比较研究

获取原文
           

摘要

To compare the effects of losartan and atenolol on plasma fibrinolytic parameters and von Willebrand factor (vWF), Chinese subjects with mild-to-moderate hypertension were randomized to receive losartan (50 mg/day; n = 30) or atenolol (50 mg/day; n = 30) for 8 weeks. If target blood pressure (< 140/90 mmHg) was not achieved at week 4, hydrochlorothiazide (12.5 mg/day) was also administered. Plasma levels of tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and vWF were determined at baseline and after treatment. Between-group baseline characteristics and blood pressure decrease were comparable. Losartan significantly reduced plasma PAI-1 and vWF and PAI-1/tPA ratio. Atenolol significantly increased plasma tPA, but PAI-1, vWF and PAI-1/tPA ratio were unchanged. In conclusion, losartan, but not atenolol improved the fibrinolytic system and reduced plasma vWF levels in Chinese hypertensives.
机译:为了比较氯沙坦和阿替洛尔对血浆纤溶参数和von Willebrand因子(vWF)的影响,将中国轻度至中度高血压患者随机分配接受氯沙坦(50毫克/天; n = 30)或阿替洛尔(50毫克/天)。天; n = 30),共8周。如果在第4周仍未达到目标血压(<140/90 mmHg),也应给予氢氯噻嗪(12.5 mg /天)。在基线和治疗后测定组织纤溶酶原激活物(tPA),纤溶酶原激活物抑制剂-1(PAI-1)和vWF的血浆水平。组间基线特征和血压下降具有可比性。氯沙坦显着降低血浆PAI-1和vWF以及PAI-1 / tPA比率。阿替洛尔显着增加血浆tPA,但PAI-1,vWF和PAI-1 / tPA比例未改变。总之,氯沙坦改善了中国高血压患者的纤溶系统,降低了血浆vWF水平,但未改善阿替洛尔。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号